欧康维视生物-B午后涨超4% 与爱尔康完成股权与产品交割

金融界
18 Oct 2024

欧康维视生物-B午后上涨4.39%,现报6.18港元,成交额507.15万港元。

10月17日,欧康维视生物-B宣布,经2024年第一次临时股东大会审议通过,公司与全球眼健康领域的引领者Alcon Inc.(简称“爱尔康”)成功完成了股权与产品交割。根据协议,欧康维视从爱尔康获得了8款产品组合在中国的研发、制造和商业化领域的相关权益。

有业内人士指出,此次交割的顺利完成,不仅丰富了欧康维视的产品管线,更显著增厚了公司在干眼等眼科重要细分领域的产品布局。通过收购这些产品,欧康维视预计将能够提供更全面和先进的治疗方案,进一步满足患者需求并扩大市场份额。

责任编辑:栎树

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10